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ABSTRACT (English Version). 
Estrogen Receptor α (ERα) is the most important diagnostic and prognostic factor in breast 
cancer. Several lines of evidence have suggested that ERα-negative breast tumors, highly 
aggressive and non-responsive to hormonal therapy, arise from ERα-positive precursors 
through different molecular pathways. microRNAs (miRs) are small non-coding RNAs that 
regulate gene expression at post-transcriptional level and are aberrantly expressed in breast 
cancer. We hypothesized that microRNAs may have a pivotal role in ERα suppression and 
ERα-negative tumors formation. MicroRNAs microarray, quantitative real-time PCR, 
immunohistochemistry and in-situ hybridization analyses of breast cancer cell lines and 
primary tumors with different ERα-status indicated that miR221&222 are exclusively 
expressed in ERα-negative breast tumors. Overexpression of both microRNAs in ERα-
positive cell lines strongly reduces the levels of ERα protein and, using luciferase reporter 
assays, we clearly demonstrated that ERα is a bona fide target of miR221&222. Gene 
expression profiles were analyzed after miR221 or miR222 over-expression in ERα-positive 
cells: up-regulation of anti-apoptotic genes, growth factors and down modulation of adhesion 
molecules indicated that miR221&222 may not only increase the ability to suppress 
apoptosis and accelerate tumor formation but also promote remodeling of the tumor 
microenvironment and escape of tumor cells through the basement membrane, all 
characteristics of ERα-negative cells. To gain more insights into the inverse correlation 
between miR221&222 and ERα in breast cancer, by computational analyses and reporter 
assay, we characterized the transcriptional unit of miR221&222. We identified several 
estrogen-responsive elements (ERE) at the genomic locus of miR221&222 and, by using 
different approaches, we demonstrated that ERα suppresses miR221&222 expression. 
Overexpression of exogenous or endogenous ERα protein in ERα-negative cells markedly 
repressed miR221&222; conversely, knockdown of ERα in ERα-positive cells increased 
their expression. Finally, chromatin immunoprecipitation (ChIP) on ERα-positive cells 
showed that ligand-bound ERα and its co-repressor proteins, NcoR and SMRT, were highly 
enriched at miR221&222 genomic locus. Notably, ChIP experiments after estradiol (E2) 
stimulation or ERα-knockdown revealed that ERα recruitment is essential for the co-
repressor enrichment and miR221&222 repression. These findings suggest that the negative 
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regulatory loop involving miR221&222 and ERα may confer proliferative advantage and 
migratory activity to breast cancer cells and promote the transition from ERα-positive to 
ERα-negative tumors. Therefore, the elucidation of this pathway could be an important step 
in the development of the next generation of breast cancer therapeutics agents that may 
prevent hormone-resistance that frequently occurs during treatment. 
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ABSTRACT (Italian Version). 
Il recettore degli estrogeni (ERα) e` il piu` importante fattore diagnostico e prognostico nel 
cancro della mammella. Numerosi studi hanno proposto che i tumori ERα negativi, 
altamente aggressivi e non-responsivi alla terapia ormonale, hanno origine da precursori ERα 
positivi. I microRNA (miRs) sono piccoli RNA non codificanti che regolano l`espressione 
genica a livello post-trascrizionale e sono espressi in maniera aberrante nel cancro della 
mammella. In questo studio abbiamo ipotizzato e dimostrato che i microRNA possano 
esercitare un ruolo importante nella soppressione dell` ERα  ed indurre la formazione dei 
tumori   ERα-negativi. A tale scopo, analisi di microarray, qRT-PCR, immunoistochimica e 
in situ-ibridazione sono state impiegate per analizzare l`espressione dei microRNA in linee 
cellulari e tumori primitivi di mammella. Tali analisi hanno evidenziato che il miR221 ed il 
miR222 sono esclusivamente espressi nei tumori della mammella ERα  negativi. L`over-
espressione di miR221 o miR222 in linee cellulari ERα-positive riduce fortemente i livelli 
proteici di ERα e, usando saggi reporter di luciferasi, abbiamo chiaramente dimostrato che 
ERα e` target diretto di miR221&222. Analisi di microarray sono state realizzate dopo 
l`over-espressione di miR221 o mir222 in linee cellulari ERα-positive: up-regolazione di 
geni anti-apoptotici, fattori di crescita e down-modulazione di molecole di adesione cellulare 
hanno indicato che miR221 o miR222 possono non solo ridurre l`apoptosi ed accelerare la 
crescita tumorale ma anche promuovere il rimodellamento dello stroma circostante la regione 
tumorale e facilitare il movimento delle cellule tumorali, tutte caratteristiche delle cellule 
ERα-negative.  
Successivamente, utilizzando analisi computazionali e saggi reporter di luciferasi, abbiamo 
identificato l`unita` trascrizionale dei miR221&222 e valutato la presenza di numerosi 
elementi responsivi agli estrogeni (ERE) nel locus genomico di miR221&222. Attraverso 
l`utilizzo di differenti approcci molecolari, abbiamo dimostrato che ERα sopprime 
l`espressione di miR221&222. In particolare, l`over-espressione di ERα in cellule ERα-
negative sopprime i livelli dei miR221&222; viceversa, la down-regolazione di 
ERa mediante RNAi in cellule ERα-positive aumenta la loro espressione. Infine, analisi di 
ChIP (Chromatin Immunoprecipitation) realizzata su linee cellulari ERα-positive hanno 
evidenziato che il recettore degli estrogeni e i suoi co-repressori, NcoR e SMRT, sono 
altamente arricchiti nella regione genomica di miR221&222. Di nota, esperimenti di ChIP 
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dopo stimolazione con estradiolo o di knockdown contro ERα hanno evidenziato che il 
recrutamento di ERα e` essenziale per il recrutamento dei co-repressori e repressione di 
miR221&222. 
Tali risultati suggeriscono che il circuito regolativo coinvolgente miR221&222 e ERα, 
conferendo alle cellule tumorali un vantaggio proliferativo e forte attivita` migratoria, 
potrebbe promuovere la transizione da tumori positivi a tumori negativi per l`espressione del 
recettore degli estrogeni. Quindi l`elucidazione di questo pathway potrebbe rappresentare un 
importante passo avanti nello sviluppo di nuove terapie anti-tumorali per il cancro al seno.   
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INTRODUCTION 
1. The discovery of microRNAs 
The discovery of microRNAs began in the early 1981 when Martin Chalfie, during a loss-of-
function study in C. elegans, discovered that mutations in lin-4 gene lead to continued 
synthesis of larval-specific cuticle 1. At that time, together with lin-14, lin-29, and lin-28, 
these genes were classified as heterochronic genes, capable to control the timing of specific 
post-embryonic developmental events in C. elegans. Seven year later, Victor Ambros 
described, in hypodermal cells, a hierarchy of interaction between the heterochronic 
regulatory genes to coordinate the “larva-to-adult switch”: the experiments have shown that, 
in the early stages of development, lin-14 and lin-28 inhibit lin-29, preventing the switch; 
next, lin-4 inhibits lin-14 and lin-28, triggering the activation of lin-29 and the following 
switch in L4 larval stage 2.  
Lin-14 has been shown to encode a nuclear protein that is normally present in most somatic 
cells of late embryos and L1 larvae but not in the later larval stages or adults. Gary Ruvkun 
found that two lin-14 gain-of-function mutations lead to an abnormal protein accumulation in 
the later larval stages; these mutations delete the 3` untranslated region of lin-14 mRNA, 
highlighting a regulatory element in the 3`UTR of lin-14 mRNA that controls the temporal 
gradient of the protein 3. Since lin-4 was described to down-regulate the lin-14 protein 
temporal levels, the authors proposed that lin-4 gene product could be the trans-acting factor 
capable to bind the 3`UTR of lin-14 and negatively regulate it.  Finally in 1993, two 
independent studies, published in the same issue of “Cell” by Ambros and Ruvkun 4 5, 
presented the real nature of lin-4 gene and its ability to regulate the heterochronic gene 
expression. After cloning the lin-4 gene, they demonstrated that the potential open-reading 
frame of lin-4 does not encode for a protein; they identified two small lin-4 transcripts of 
approximately 22 and 61 nt and found that the 3` UTR of lin-14 mRNA contains sequences 
complementary to lin-4 small RNA products. According to these data, the authors suggested 
that the temporal regulation of lin-14 is operated at the protein translation level driven by lin4 
RNA via antisense RNA-RNA interactions, involving the small RNA lin-4 and the 3`UTR of 
lin-14. Seven years latter, Reinhart et al. showed that let-7 gene, another heterochronic 
switch gene, is coding for a small 21 nt RNA with complementary sequence to the 3`UTR of 
lin-14, lin-28, lin-41, lin-42 and daf-12; they proposed that the sequential stage-specific 
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expression of let-7 and lin-4 RNAs was capable through an RNA-RNA interaction with the 
3`UTR of the target genes to trigger the temporal cascade of regulatory heterochronic genes 
specifying the timing of C. elegans developmental events 6. 
At that time, these discoveries were considered as a new piece in the complicated gene 
expression regulation puzzle restricted to the small temporal RNA let-7 and lin-4 (stRNA) in 
worms. This idea was completely changed when independent groups tried to investigate 
whether RNAs similar to stRNA could play a more general role in gene regulation 7,8 9. 
Isolating and cloning the small RNA from different organisms and cellular systems, by using 
the same strategy applied to clone siRNA processed from exogenous dsRNAs in an embryo 
lysate, researchers in three laboratories were able to isolate a group of RNAs with the same 
characteristics of lin-4 and let-7, providing evidence for the existence of a large class of small 
RNAs with potential regulatory roles. Because with their small size, the authors referred to 
these novel RNAs as microRNA (abbreviated miRNAs), a new abundant class of 
riboregulators that could regulate the gene expression at post-translational level by base-
pairing the 3`UTR of mRNA targets. After this discovery, a new challenge for the 
researchers was to define the biological function and the potential target genes of these new 
genes. 
2 MiRNAs: GENOMICS, BIOGENESIS AND MECHANISM OF ACTION 
2a. How many miRNAs are enough? 
At the beginning, the majority of microRNAs was identified by direct cloning of small 
RNAs10; this approach was very reductive because it permitted just the detection of abundant 
expressed miRNAs. Three observations suggested that miRNAs genes could be identified 
using computational approaches. First, miRNAs are produced from a precursor transcript of 
70-100 nt with extended stem-loop structure. Second, miRNAs are usually highly conserved 
between the genomes of related species. Third, miRNAs display a characteristic pattern of 
evolutionary divergence. In according with these criteria, many computational procedures 
have been developed to predict miRNAs genes in the genome of different organisms, like 
MiRNAscan in humans, miRNAseeker in Drosophila or others in C. elegans (for review see 
11,12). The sensitivity of these bioinformatic approaches was demonstrated by the presence of 
a high percentage of previously experimentally identified miRNAs within the top predicted 
candidates and by confirmation using Northern blotting analysis and a more sensitive RT-
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PCR method. The estimate of miRNA genes in the metazoan genome represents nearly 1% 
of the predicted genes, a fraction similar to that seen for other very large gene families with 
regulatory roles, such as those encoding transcription-factor proteins. 
In 2003, the rapid growth of the miRNA genes number has led Sam Grifftihs-Jones from 
Wellcome Trust Sanger Institute to create a comprehensive and searchable database of 
published miRNAs sequences via a web interface, “The microRNA Registry” 
(http://www.sanger.ac.uk/software/Rfam/mirna/) 13. The primary aims of this registry are 
two-fold. The first is to avoid inadvertent overlap by assigning unique names to distinct 
miRNAs. The microRNAs are annotated with numerical identifiers based on sequence 
similarity: a standard name is like “miR-15” and the next miR without similarity will receive 
the name “miR-16”. For homologue miRNAs in different organisms, it is usual to assign the 
same name on the similarity of the 22 nt mature sequence. Identical mature forms are 
assigned the same name and if they are produced from different genomic loci they are 
differentiate by suffixes as, for example, “miR-15-1” and “miR-15-2”. Differences in one or 
two bases are identified by suffixes, such as “miR-181a” and “miR-181b”. If a microRNA 
hairpin precursor give rise to two mature miRNAs, one from each arms, the rule is to denote 
miRNAs in the form “miR-142-5p” (5` arm) and “miR-142-3p” (3` arm) until the expression 
data will confirm which form is predominantly expressed; in such cases, the specie less 
expressed will be identified by using an asterisk (such as “miR-191*”). The second aim of 
miRNA registry is to provide an all miRNAs sequences database including the stem-loop 
structure, with the highlighted microRNA in red, genomic location, homologous sequences 
and possible target predictions. 
At the beginning of 2005, a phylogenetic shadowing study on microRNAs in primate species 
revealed a characteristic conservation profile of miRNAs genes that the authors have used to 
efficiently detect the 83% of the known miRNAs and predict an extensive set of novel 
miRNAs, opening the possibility that as many as 1000 microRNAs may exist in the human 
genome 14. The MicroRNA Registry contained in the version 12.0 (September 2008) 8619 
entries from in primates, rodents, birds, fish, worms, flies, plants and viruses; actually, the 
human miRNAs are 695 and the number may still increase. 
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2b. Genomics of microRNAs. 
Almost 50% of mammalian microRNAs are located in introns of protein coding genes or 
long ncRNAs transcripts, whereas the remaining part is considerable as indipendent 
transcription units with specific promoter core elements and polyadenilation signals (for 
review see 15-17).  Among the intragenic miRNAs, 40% are found in introns of protein coding 
genes, whereas ~10% are located in introns of long ncRNA transcripts. The vast majority of 
miRNA clusters are single transcription units or overlapped in the same host transcripts, 
within exons or introns, and in some cases depending on alternative splicing of the host gene, 
implying that they are transcribed as polycistronic transcripts. Additionally, many miRNAs 
overlap with two or more transcription units transcribed on opposite DNA strands.  
The analysis of miRNAs genomic loci evidences that host genes encoding proteins are 
involved in a broad spectrum of biological function ranging from embryonic development to 
the cell cycle and physiology. When the miRNAs host genes are classified for Gene 
Ontology (GO) “biological process”, the two most commonly identified biological process 
are “metabolism” and “cellular physiological process” whereas the classification for GO 
“molecular function” identifies “purine nucleotide binding” and “DNA binding” proteins.  
In addition to the miRNAs located in protein coding genes, a large group of microRNAs 
resides in transcripts that lack a significant protein-coding potential, classified as long 
ncRNAs. These types of ncRNA transcripts are sometimes referred to as mRNA-like 
ncRNAs (mlncRNA) because they are spliced, polyadenilated and also spatio-temporally 
expressed. Deleted in Leukemia 2 (DLEU2) and BIC are host-genes mlncRNAs respectively 
for miR-15/miR-16 cluster and miR-155 18, 19. 
The maturation of miRNAs is a very complex process and in the following sections we will 
try to illustrate the machinery that the cell needs to activate the intricate multi-step processing 
from nucleus to cytoplasm, required for the production of microRNAs. 
2c. MicroRNAs Transcription and Maturation. 
Initially, the researchers believed that microRNAs were transcribed by RNA polymerase III 
like other small RNAs, as some as tRNAs. However, numerous evidences supported the 
possibility of a transcription mediated by RNA polymerase II. In 2004, three direct evidences 
have been reported to evaluate the strict correlation between microRNAs and pol II: (i) the 
miRNAs transcripts are capped and polyadenilated; (ii) the transcription of miRNAs 
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transcripts is sensitive to alpha-amanitine at the specific concentration for pol II inhibition; 
(iii) the promoter region, responsible for miRNA transcription, is associated to pol II 
complex 15.  
Animal microRNAs are identified as part of 80 nt RNA with stem-loop structure (pre-
miRNA) that are included in several hundreds/thousands nucleotide long miRNAs 
precursors, named primary miRNAs precursor (pri-miRNA) (Figure 1). Until now, few 
different pri-miRNA precursors have been isolated and characterized. They are all capped, 
polyadenilated and apparently non-coding: the human cluster miR-23a~27a~24-2 primary 
precursor is an unspliced ~2.2 kb RNA; in contrast, the pri-miRNA for human miR-155 
(BIC) includes two introns and two alternative poly-A sites capable to produce two spliced 
pri-miRNAs of 0.6 and 1.4 kb 16.  
The production of microRNAs from pri-miRNA to mature miR is a complex and coordinated 
process where different groups of enzymes and associated proteins, located in the nucleus or 
cytoplasm, operate the multistep maturation of these tiny RNAs. Principally, the maturation 
process of microRNAs can be resumed in three important steps: cropping, export and dicing 
(Figure 1).  
In the cropping, the pri-miRNA is converted in pre-miRNA trough the cleavage activity of 
Drosha enzyme, a nuclear Ribonuclease III endonuclease capable to crop the flank regions of 
pri-miRNA in turn to liberate the 60-70 nt pre-miRNA 10. Different pri-miRNA requisitions 
are necessary to obtain an efficient precursor maturation by Drosha: first, a large terminal 
loop (> 10 nucleotides) in the hairpin and a stem region one turn bigger than the pre-miRNA; 
second, a 5` and 3` single stranded RNA extensions at the base of the future microRNAs 20, 
21. It has been proposed that Drosha may recognize the primary precursor through the stem-
loop structure and then cleave the stem at a fixed distance from the loop to liberate the pre-
miRNA. How the enzyme is capable to discriminate the pri-miRNA stem-loop structure in 
respect to the others stem-loop cellular RNAs is not clear, but probably proteins associated 
with Drosha confer specificity to this process. In fact, Drosha has been found as a part of 
large protein complex of ~650kDa, which is known as the “Microprocessor”, where Drosha 
interacts with its cofactor, the Di George syndrome critical region gene 8 (DGCR8) protein 
in human and Pasha in Drosophila melanogaster 22. The Microprocessor appears to represent 
a heterotetramer consisting of two Drosha and two DGCR8 molecules;  because DGCR8  
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FIGURE 1. MicroRNA (miRNA) genes are transcribed by RNA polymerase II (pol II) to generate 
the primary transcripts (pri-miRNAs). The initiation step ('cropping') is mediated by the 
Drosha?DGCR8 complex (also known as the Microprocessor complex). Drosha and DGCR8 are both 
located mainly in the nucleus. The product of this nuclear processing step is a 70-nucleotide (nt) pre-
miRNA, which possesses a short stem plus a 2-nucleotide 3' overhang. This structure might serve as a 
signature motif that is recognized by the nuclear export factor exportin-5. Pre-miRNA constitutes a 
transport complex together with exportin-5 and its cofactor Ran (the GTP-bound form). Following 
export, the cytoplasmic RNase III Dicer participates in the second processing step ('dicing') to 
produce miRNA duplexes. The duplex is separated and usually one strand is selected as the mature 
miRNA, whereas the other strand is degraded. 
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contains two consensus dsRNA binding domain, this protein may play an important role in 
the substrate discrimination and binding.  
The resulting product of cropping, the pre-miRNA, presents a 5` phosphate and 3` hydroxy 
termini, and two or three nucleotides single-stranded overhanging ends, classic 
characteristics of Rnase III cleavage of dsRNAs. After the Microprocessor nuclear activity, 
the produced pre-miRNA is exported to the cytoplasm by Exportin-5/RnaGTP23. Exp-5 
forms a nuclear heterotrimer with RanGTP and pre-miRNA, resulted from Drosha 
processing. This interaction, which is dependent on RNA structure but independent of 
sequence, stabilizes the nuclear pre-miRNA and promotes the export to the cytoplasm.  In 
any export, once the Exp5-RanGTP-pre-miRNA complex has reached the cytoplasm through 
the nuclear pore, the RnaGTP is hydrolyzed to RanGDP and the pre-miRNA is released.  
Arrived into the cytoplasm, the pre-miRNA is processed in 18~22 nucleotides miR duplexes 
by the cytoplasmic Rnase III Dicer and, in humans, its partner TRBP. The PAZ domain of 
Dicer is thought to interact with the nucleotides 3` overhang present in the pre-miRNA 
hairpin while the dsRNA binding domain binds the stem and defines the distance of cleavage 
from the base of pre-miRNA.  The cleavage 22nt-long miRNA duplexes have a reduced half-
life. Normally, one strand of this duplex is degraded whereas the other strand accumulates as 
a mature miRNA. Studies on siRNAs have highlighted that the selection of the right strand is 
related to the thermodynamic stability of the duplex and the strand with relatively unstable 
base pairs at the 5` end usually represents the mature miR. 
2d. MicroRNA in action: RISC and gene target inhibition 
In the RNA duplex produced from the Dicer activity, the mature miRNA is only partially 
paired to the miRNA*, the small RNA that resides on the opposite pre-miRNA stem. From 
the miRNA-miRNA* duplex, only the miRNA enters preferentially in the protein effector 
complex, the RNA Induced Silencing Complex (RISC) or miRNAsC or miRgonaute, which 
mediates the degradation or translation inhibition of mRNAs target gene24. Several proteins 
have identified as essential components of RISC, but only a few have been functionally 
characterized in the post-translational regulation. The core component of every RISC is a 
member of the Argonaute (Ago) protein family, whose members present a central PAZ 
domain like Dicer and a carboxy terminal PIWI domain. This domain binds the miR/miR* 
duplex to the 5` end whereas the PAZ domain binds to the 3` end of singled-strand RNAs; 
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moreover, structural and biochemical studies have suggested that the Ago proteins are the 
target-cleaving endonuclease of RISC and in this activity the complex is helped and 
coordinated by other proteins whose function is not really understood like RNA-binding 
protein VIG, the Fragile-X related protein in Drosophila, the exonuclease Tudor-SN and 
many other putative helicases25. In the human cells, after the microRNAs transfection by 
miR-expressing vectors or miRNA precursors, and the following activation of RISC activity, 
the core component of RISC, together with the triggering miRNA target mRNA, is 
concentrated in cytoplasmic foci known as Processing bodies (P-bodies) or GW-bodies. 
According with this triggered RISC localization, the researchers thought that the 
microRNAs, in association with AGO proteins, might be capable to repress the translation at 
ribosomal level and to re-localize the mRNA targets to the P-bodies26.  
The majority of the animal miRNAs are imperfectly paired to the 3` UTR of the target 
mRNA and inhibit the protein production by an unknown or very controversial mechanism 
(Figure 2); in some cases, the microRNAs show nearly precise complementarity to their 
target and trigger mRNA degradation as siRNA in the RNA interference process24. 
The most important characterization of the function of microRNAs is the identification of 
mRNA target. Because the animal miRNAs have a 5`end restricted complementarity to the 
mRNA target (only 5-8 nucleotides perfectly complementary), RNA sequence named “seed 
region”, the miRNAs are predicted to regulate a large number of animal genes. Different 
algorithms have been developed to predict the animal miR targets; they are based on different 
criteria, resulted from the analysis of the in vivo demonstrated targets: (i) perfect or nearly 
perfect base-paring at the seed region and thermodynamically stability of the duplex miR-
mRNA; (ii) phylogenetic conservation of the seed region; (iii) multiple target sites in a single 
target by the same or different miRNAs; (iiii) absence of strong secondary structures at the 
miR-binding site on the target. Several computational procedures are available to predict 
microRNA targets such as DianaMicroT (http://www.diana.pcbi.upenn.edu/cgi-
bin/micro_t.cgi), TargetScan (http://genes.mit.edu/targetscan/), and miRanda 
(http://genes.mit.edu/targetscan/) 27-29. 
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FIGURE2. Mechanisms of miRNA-Mediated Gene Silencing. (A) Postinitiation mechanisms. MicroRNAs (miRNAs; 
red) repress translation of target mRNAs by blocking translation elongation or by promoting premature dissociation of 
ribosomes (ribosome drop-off). (B) Cotranslational protein degradation. This model proposes that translation is not 
inhibited, but rather the nascent polypeptide chain is degraded cotranslationally. The putative protease is unknown. (C–E) 
Initiation mechanisms. MicroRNAs interfere with a very early step of translation, prior to elongation. (C) Argonaute 
proteins compete with eIF4E for binding to the cap structure (cyan dot). (D) Argonaute proteins recruit eIF6, which 
prevents the large ribosomal subunit from joining the small subunit. (E) Argonaute proteins prevent the formation of the 
closed loop mRNA configuration by an ill-defined mechanism that includes deadenylation. (F) MicroRNA-mediated 
mRNA decay. MicroRNAs trigger deadenylation and subsequent decapping of the mRNA target. Proteins required for 
this process are shown including components of the major deadenylase complex (CAF1, CCR4, and the NOT complex), 
the decapping enzyme DCP2, and several decapping activators (dark blue circles). (Note that mRNA decay could be an 
independent mechanism of silencing, or a consequence of translational repression, irrespective of whether repression 
occurs at the initiation or postinitiation levels of translation.) RISC is shown as a minimal complex including an 
Argonaute protein (yellow) and GW182 (green). The mRNA is represented in a closed loop configuration achieved 
through interactions between the cytoplasmic poly(A) binding protein (PABPC1; bound to the 3? poly(A) tail) and 
eIF4G (bound to the cytoplasmic cap-binding protein eIF. 
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3. microRNAs: function in normal and disease states. 
With the discovery on a “daily - basis” of new members of the miRNA family, it becomes 
evident that these small genes are involved in normal cells homeostasis 10, 30. Furthermore, 
with the development of new techniques of genome-wide screening of microRNAs 
expression, abnormal levels of microRNAs were identified in tumor cells in respect with 
normal counterparts 31- 33. The functions of microRNAs, initially a “shadow” area of 
research, revealed a general participation in every functional aspect of normal cells in 
organisms with different degrees of complexity. For example, in Drosophila, miR-14 
suppresses cell death and is required for normal fat metabolism34 , while bantam encodes a 
developmentally regulated microRNA that controls cell proliferation and regulates the 
proapoptotic gene hid35. As Shown in Table 1, miRNAs participation in essential biological 
processes have consistently been proven, such as cell proliferation control (miR-125b and let-
7), hematopoietic B-cell lineage fate (miR-181), B-cell survival (miR-15a and miR-16-1), 
brain patterning (miR-430), pancreatic cell insulin secretion (miR-375) and adipocyte 
development (miR-143) (for reviews see 36-38).  
As a consequence of extensive participation in normal functions, it is quite logical to ask the 
question if microRNAs abnormalities should have importance in human diseases. As shown 
in Table 2, microRNAs and/or proteins involved in the processing of miRNAs are involved 
in various types of human diseases, the most studies example being human cancers.  
MiRNAs can act both as tumor suppressors and oncogenes 31-33.  
Homozygous deletions (as is the case for miR-15a/miR-16a cluster), the combination 
mutation + promoter hypermethylation or gene amplification (as is the case of miR-155 or 
the cluster miR-17-92) seems to be the main mechanisms of inactivation or activation, 
respectively 39-41. Because of the small size, the loss-of-function or gain-of-function point 
mutations represent rare events 42. MiRNAs activity can be influenced either by the 
reposition of other genes close to miRNAs promoters/regulatory regions (as is the case of 
miR-142s – c-MYC translocation) or by the relocalization of a microRNA near other 
regulatory elements.  The overall effects in the case of miRNAs inactivation is the 
overexpression of target mRNAs, while the miRNAs activation will lead to downregulation 
of target mRNAs involved in apoptosis, cell cycle, invasion or angiogenesis.  
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To date, it was elegantly demonstrated that let-7 microRNA family regulates RAS oncogenes 
and that let-7 expression is lower in lung tumors than in normal lung tissue, while RAS 
protein has an inverse variation 43. Furthermore, enforced expression of the miR-17-92 cluster 
from chromosome 13q32-33 in conjunction with c-myc accelerates tumor development in a 
mouse B-cell lymphoma model 40.  Two microRNAs from the same cluster, miR-17-5p and 
miR-20a negatively regulates the E2F1 transcription factor, a gene proved to function as a 
tumor suppressor in some experimental systems 39.Recently, an unexpected mechanism of 
involvement of miRNAs in human disease was identified. Tourette syndrome is a neurologic 
disorder manifested particularly by motor and vocal tics and associated with behavioral 
abnormalities. Sequence variants of a candidate gene on chromosome 13q31.1 named 
SLITRK1 (Slit and Trk-like 1) were identified in patients with TS. One of them, named 
var321, found in two unrelated patients, was located in the 3’UTR binding site for the miR-
189 and might affect SLITRK1 expression 44. This mechanism of abnormal miRNA::mRNA 
interaction seems to be a general one, as it was proved also in the case of oncogene c-KIT. 
Three of the highly overexpressed miRNAs in thyroid cancers, miR-221, miR-222 and miR-
146, are predicted to interact with KIT oncogene mRNA at two different sites. Tumors in 
which the up-regulation of these miRNA was the strongest showed dramatic loss of KIT and 
in half of the cases the down-regulation was associated with germline single nucleotide 
polymorphysms (SNP) in the two recognition sites in KIT for these three miRNAs 45. One 
important proof for the functional importance of such abnormalities is represented by the 
reproduction of similar diseases in mouse models with abnormal microRNAs expression. 
Recently, the first example of transgenic microRNA mouse was published: as expected by 
the overexpression of miR-155 in human lymphomas 19 46, the miR-155 transgenic mice 
overexpressing the gene only in B cells, exhibit a preleukemic pre-B cell proliferation in 
spleen and bone marrow, followed by frank B cell malignancy 47. These findings indicate that 
the role of miR155 is to induce polyclonal expansion, favoring the capture of secondary 
genetic changes for full transformation. This is the final proof that deciphering miRNA 
alterations is important and that miRNAs, as small as they are, represent big culprits in 
human diseases. 
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AIM OF THIS STUDY 
Breast cancer is the second leading cause of death among women with cancer in western 
world and its molecular pathogenesis is still not completely understood. Breast cancers arise 
from the mammary gland epithelium and its complex cellular hierarchy is becoming evident 
during breast tumorigenesis. For example, several intensive studies to determine gene-
expression profiles of breast tumors enabled classification of, at least, five reproducible 
subtypes including luminal A, luminal B, basal-like, Her2+, and normal basal-like48,49, which 
partially correlate with the traditional histological classification of the tumor50. Overall, such 
studies pointed out that Estrogen Receptor α (ERα) expression status is one of the strongest 
factors governing the gene expression profile in breast cancer51 and thus, determines the 
biopathological phenotype of the tumor.   
ERα is a nuclear hormone receptor that mediates the mitogenic action of 17β-estradiol on the 
breast ductal epithelium. E2-bound ERα is involved not only in the epithelial cells 
development but also in progression of breast cancer52. About 75% of diagnosed breast 
tumors are ERα positive and the expression of ERα is correlated with a better prognosis 
mainly because of the likelihood of response to hormonal treatment53. Different studies 
suggest that a fraction of ERα-negative tumors arise from ERα-positive precursors54. Several 
molecular events, such as estrogen withdrawal55, hypoxia56, overexpression of epidermal 
growth factor receptor (EGFR) or ErbB2, which brings hyperactivation of mitogen activated 
protein kinase (MAPK)57 and DNA methylation occurring at the promoter of ERα gene58, 
have been reported to suppress ERα expression. 
miRNAs play a pivotal role in tumorigenesis of breast cancer.  Iorio et al. have previously 
determined miRNA expression profiles of breast cancer tissues59. This study demonstrated 
that miRNAs were aberrantly expressed in breast cancer as compared to miRNAs expressed 
in normal tissue and, more interestingly, miRNA expression pattern could discriminate 
between breast tumors with different bio-pathologic phenothypes such as ERα status. A 
recent study further showed that miR-206, identified as an upregulated miRNA in ERα-
negative tumors59, targets ERα mRNA60. 
Here, we have determined microRNA expression profiles of a set of breast cancer cell lines 
with different ERα expression status and found a remarkable and consistent up-regulation of 
miR221&222, exclusively in ERα-negative cell lines. Demonstration of the suppressive 
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effect of miR221&222 on ERα protein and the identification of miR221&222 responsive 
target sites in the 3’UTR of ERα mRNA led us to conclude that ERα is a bonafide target of 
miR221&222. We showed that overexpression of miR221&222 in ERα-positive cells 
induces a global change in gene expression that differs from miR206 signature and may 
account for the generation of a more invasive and deadly tumor phenotype. Furthermore, we 
showed that ERα directly binds to the promoter of miR221/222 gene and recruits co-
repressors NCoR and SMRT, thereby functioning as a transcriptional repressor for 
miR221/222 gene. Taken together, our results uncovered the presence of a regulatory loop 
composed of miR221&222 and ERα in human breast cancer cells, which may provide a new 
insight into understanding how breast cancer cells determine ERα-positive and-negative 
status. 
METHODS 
Cell Culture and Tumor Samples 
 Human breast cancer cell lines (T47D, MCF7, BT-474, BT483, MDA-MB-231, MDA-MB-
436, MDA-MB-468) were purchased from ATCC and grown in DMEM containing 10% 
heat-inactivated FBS, 2mM L-glutamine and 100U/ml penicillin/streptomycin.  All 
transfections were carried out with Lipofectamine 2000 (Invitrogen) according to the 
manifacturer’s instructions. For estradiol treatments, cells were grown to 70% confluency in 
phenol red-free Dulbecco's modified Eagle medium (DMEM) supplemented with 5% 
charcoal-dextran-stripped fetal bovine serum for at least 5 days. Meg01 cells were purchased 
from ATCC and grown in RPMI 1640 containing 10% heat-inactivated FBS, 2mM L-
glutamine, 100U/ml penicillin/streptomycin. For proliferation assay, MCF7 were plated in 
96-well plates and grown for 96hrs after transfection (miR final concentration 100nM) in 
normal culture condition. Cell growth was measured using Celltiter 96 AQueous Non-
Radicative Cell Proliferation Assay (Promega), according to manifacturer`s instructions.  
Cell Cycle was performed on propidium iodide stained, ethanol-fixed cells. All tumors 
samples were obtained with patient consent from the Department of Experimental Oncology, 
Fondazione IRCCS “Istituto Nazionale dei Tumori”, Milano. All samples were histologically 
confirmed. 
Plasmid Constructions 
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 To generate the ERα luciferase reporter constructs, two potential binding sites for 
miR221&222 within the 3` UTR of ERα mRNA were amplified by PCR and cloned 
downstream of the luciferase coding sequence in the pGL3-control vector (Promega).  
Mutations were introduced into the miRNA binding sites by using QuikChange mutagenesis 
kit (Stratagene). For mapping miR221/222 gene promoter, upstream genomic sequence of 
miR222 hairpin was amplified by PCR and cloned at the NheI and XhoI sites of pGL3-basic 
vector (Promega). To construct the pCRUZ-HA-ERα, ERα cDNA from ATG to TGA was 
synthesized from MCF7 mRNA by RT-PCR and was cloned in frame at the KpnI and 
EcoRV sites of pCRUZ-HA (Santa Cruz Inc). All constructs were sequenced to verify their 
integrities.  
Microarray Analysis 
For microRNAs microarray analysis61, total RNAs from 6 breast cancer cell lines were 
hybridized to the Ohio State University custom miRNA microarray chip (OSU_CCC version 
3.0), which contains 1150 miRNA probes, including 326 human and 249 mouse miRNA 
genes, spotted in duplicates. Differentially expressed miRNAs were identified using the 
Class Comparison Analysis of BRB tools version 3.6.0 (http://linus.nci.nih.gov/BRB-
ArrayTools.html). The criteria for inclusion of a gene in miRs list is a p-value lower than a 
specified threshold value (0.05). A tree cluster was generated by the hierarchical cluster 
analysis; for this analysis, we used average linkage metrics and centered Pearson correlation 
(Cluster 3.0). Java Treeview 1.1 was used for tree visualization. The labeling of mRNA and 
the hybridization of the labeled cRNA onto the Affymetrix GeneChip HG-U133A 2.0 arrays 
were performed according to Affymetrix standard protocols (Santa Clara, CA). BRB 
Arraytools was used for Affymetrix HU133Plus2 genechips. Normalization was performed 
by GC-RMA and genes showing minimal variation across the set of arrays were excluded 
from the analysis. Genes whose expression differed by at least 1.5 fold from the median in at 
least 20% of the arrays were retained. Genes were considered statistically significant if their 
p-value was lower than 0.001 (False detection rate<0.01). All differentially expressed genes, 
either up- or down-regulated, along with their corresponding fold-change values, were input 
into Pathway-Express, a program that automatically determines the most related pathways 
based on pathway topology, gene expression level (fold-change), and relative positions of 
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genes within a pathway(s).  Returned pathways were considered significant if the corrected 
gamma-p-value was less than 0.01. Pathways were then ranked according to impact factor.  
Real Time PCR 
For quantitative detection of mature miRNA, real-time PCR was performed using the 
TaqMan PCR Kit, followed by the detection with Applied Biosystems 7900HT Sequence 
Detection System (P/N: 4329002, Applied Biosystems). PCR was carried out in 10 µl 
reaction containing 0.67 µl RT product, 1 µl TaqMan Universal PCR Master Mix (P/N: 
4324018, Applied Biosystems), 0.2 mM TaqMan probe, 1.5 mM forward primer and 0.7 mM 
reverse primer. The reaction mixture was incubated in a 96-well plate at 95 ˚C for 10 min, 
followed by 40 cycles of denaturation (95 ˚C for 15 s) and extension (60 ˚C for 1 min). All 
reactions were run in triplicate. The comparative CT method for relative quantization of gene 
expression (User Bulletin #2, Applied Biosystems) was used to determine miRNA expression 
level. Simultaneously determined U6 CT was used to normalize the data. For quantification 
of ERα, pS2 and GAPDH mRNAs, the appropriate TaqMan probes were purchased from 
Applied Biosystems. 
Luciferase Assays 
 For identification of miR221&222 responsible elements, Meg01 cells were cotransfected in 
24 well plates with 250ng of pGL3 reporter vector carrying the miR221 &222 binding site 
(see plasmid construct), 25ng of the phRL-SV40 control vector (Promega), and 100nM miR 
precursors or scramble control (Ambion) using Lipofectamine 2000. For mapping 
miR221/222 gene promoter, Meg01 cells were cotransfected in 24 well plates with 250ng of 
pGL3 reporter vector carrying upstream genomic sequence of miR222 hairpin (see plasmid 
construct) and 25ng of the phRL-SV40 control vector. Firefly and Renilla luciferase 
activities were measured consecutively by using Dual Luciferase Assay (Promega) 24h post-
transfection. Reporter assay were carried out in triplicate.  
 
Acrylamide and Agarose Northern Blot Detection.  
For mature miRNA detection, acrilamide Northern blotting was performed as previously 
described [16]. Briefly, 10 µg aliquots of total RNAs from cell lines were resolved in a 15% 
denaturing polyacrylamide gel (Bio-Rad) and were electrophoretically transferred to bright-
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Star blotting membrane (Ambion). The oligonucleotide encoding the complementary 
sequence of the mature miRNA annotated in miRNA Registry was end-labeled with [γ32 P]-
ATP by T4 polynucleotide kinase (USB,Cleveland). RNA blotted membrane was 
prehybridized in Ultrahyb Oligo solution (Ambion) and subsequently hybridized in the same 
solution containing probe at a concentration of 106 cpm/ml at 37˚C, overnight. Membrane 
was washed at high stringency in the solution containing 2X SSC and 1% SDS at 37˚C. 
Northern hybridization signals was captured and converted to digital image by using 
Typhoon Scanner. For the detection of primary transcript of miR221&222, total RNA (10 µg 
per sample) was size-fractionated through 1.2% agarose-formaldehyde gels and transferred to 
Amersham nylon filters. Northern blot was hybridized with random-primed and α-32P-
labeled genomic DNA fragment spanning either miR221 or miR222 hairpin, as a probe 
(Roche).  
ChIP Assay  
ChIP assays were performed by using the ChIP assay kit from Upstate Biotechnology (Lake 
Placid, NY) with minor modifications. Briefly, cells were grown to 70% confluency in 
Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum. 
The cross-linking was performed with 1% formaldehyde at 37°C for 10 min. Cells were then 
rinsed with ice-cold PBS and resuspended in 0.4 ml of lysis buffer containing 1% SDS, 10 
mM EDTA, 50 mM Tris-HCl, pH 8.1, 1xprotease inhibitor cocktail (Roche Molecular 
Biochemicals, Indianapolis, IN) and sonicated. A 30µl aliquot of the preparation was treated 
to reverse the cross-linking, deproteinized with proteinase K, extracted with phenol 
chloroform, and determined for DNA concentration. An aliquot of chromatin preparation 
containing 25 µg DNA was used per ChIP. DNase-free RNase (Roche) was added at a 
concentration of 200 µg/ml during reverse cross-linking. After deproteinization with 
proteinase K, DNA was purified in 50 µl of Tris-EDTA with a PCR purification kit (Qiagen, 
Valencia, CA) according to the manufacturer's instructions. A 2-µl aliquot was used for PCR. 
Primer sequences are listed in Supplementary Experimental Procedures. The primary 
antibodies used for immunoprecipitation were ERα (Bethyl laboratories A300-498A), SMRT 
(Santa Cruz Inc. sc-20778), NCoR (Santa Cruz Inc. sc-8994), rabbit IgG control (Zymed).  In 
some experiments, ChiP-enriched DNA was also subjected to qPCR by using SYBR reagent 
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(Applied Biosystem). In this case, results were expressed as relative enrichment according to 
the following formula: 2^ -[(ctChIP-ctinput)-(ctIgG-ctinput)].  
Results 
Up-Modulation of miR221&222 in ERα-negative Cells and Primary Tumors. 
First, we determined miRNA expression profiles of a small set of human breast cancer cell 
lines with different ERα expression status. MicroRNA microarray analysis of ERα-positive 
cell lines (T47D, BT474 and BT483) and ERα-negative cell lines (MB-468, MB-436 and 
MB-231) was performed by using our custom miRNA microarray platform61. Hierarchical 
clustering analysis based on the miRNA expression data distinguished sharply ERα-negative 
from ERα-positive cell lines (Figure 3a). MiRNAs displaying more than 4-fold change of 
difference are listed in Table 3. As shown previously59, we also identified miR191  and 
miR26a as up-regulated miRNAs in ERα-positive breast cancer cells (Figure 3a and Table 
3). We also noted that the expression level of miR206, up-regulated in ERα-negative breast 
cancer59 and later shown to target ERα transcript60, was up-regulated in ERα-negative cells 
(Figure 3b) with statistical significance, although it was excluded from the list due to the 
current cut-off setting. Among up-regulated miRNAs in the ERα-negative cells, 
miR221&222 were identified as the miRNAs displaying the highest differential expression 
against the ERα-positive counterpart (Figure 3a,b and Table 3). Validation of the 
microarray results was performed by northern blot analysis and, further, by qRT-PCR for the 
most differentially and biologically relevant microRNAs, miR191, miR203, miR221 and 
miR222 (Figure 3c,d). Both analyses confirmed that miR221&222 were detectable only in 
the ERα-negative cells. Then, we wished to determine whether the observation was also 
extended to breast cancer tissues. To this end, qRT-PCR of miR221&222 was performed on 
66 breast cancer tissues, including 44 ERα-positive and 22 ERα-negative tumors (Table 4). 
Results showed that the expression level of miR221&222 differentiates the two cohorts at 
statistical significance, according to the ERα status (Figure 3e).  No other statistically 
significant correlations with the other patient`s or tumor`s characteristics were found.  These 
results indicated that the up-regulation of miR221&222 in ERα-negative cells is a common 
feature both in established breast cancer cell lines and primary breast cancer tissues. 
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ERα  Is Target of miR221&222.  
The consistent and highly differentiated expression of miR221&222 in ERα-negative cells 
raised the possibility of a role for miR221&222 in the loss of ERα in ERα-negative cells. To 
this end, two ERα-positive cell lines, T47D and BT474, lacking miR221&222 expression, 
were transfected with either pre-miR221, pre-miR222 or scrambled control. qRT-PCR 
analyses showed highly efficient production of mature miR221 or miR222 in both transfected 
cell lines (Figure 4a). Subsequent western blot analysis demonstrated that enforced 
expression of miR221 or miR222 caused remarkable reduction of ERα protein (Figure 4b). 
Furthermore, an additional ERα-positive cell line, MCF7, was treated by using the same 
procedures as described above. Cells were collected at different time points (24, 48, 72, and 
96hrs) and the levels of ERα protein, assayed by western blot (Figure 4c), were undetectable 
96hrs after transfection. qRT-PCR was also carried out on the same samples in order to 
evaluate the effect of miR221&222 overexpression on ERα mRNA (Figure 4d and data not 
shown). Since ERα mRNA levels were slightly reduced only after 96hrs of transfection 
(about 20% of reduction), the effect of miR221&222 on ERα protein reduction was due 
primary to a translational block and not to an ERα mRNA degradation. 
MiR221 and miR222 share an identical seed sequence of 8 nucleotides and are predicted by 
bioinformatic algorithms (PicTar and TargetScan4.2) to bind to the ERα-3'UTR at two 
different sites, referred to as cER3’UTR and ncER3’UTR, respectively (Figure 4e). 
cER3’UTR is highly conserved across several species while ncER3’UTR is poorly conserved 
(Figure S1). Subsequent luciferase reporter assays showed that the insertion of both sites 
resulted in miR221- and miR222- dependent inhibition of luciferase activity (Figure S1, 
Figure 4f, g light and dark green columns). Importantly, mutation of the seed sequences 
against miR221 and miR222 markedly reduced their inhibitory effect (Figure S1, Figure 4f, 
g light and dark yellow columns). We concluded that miR221&222 target ERα through the 
two elements localized within the 3’ UTR of ERα mRNA and that up-regulation of 
miR221&222 in ERα-negative cells may play a role in loss of ERα expression. 
Differential Effect of miR221&222 and miR206 on Gene Expression in Breast Cancer  
As previously described, ERα is also targeted by miR20660. To determine the differential 
effect of miR221&222 and miR206 on ERα production and their impact on breast 
tumorigenesis, MCF7 were transfected with miR221, miR222, miR206 and scrambled  
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control. This study clearly showed that all these miRNAs suppress ERα protein at the same 
levels (Figure 5a). Recently, several studies have shown that miR221&222 target as well the 
tumor suppressor protein p27Kip1 62-65. These studies pointed out that a high level of 
miR221&222 are required to maintain low levels of p27Kip1 protein, allowing for cancer cell 
proliferation and tumor growth. We found that p27 Kip1 protein was repressed only in cells 
expressing miR221&222 but not miR206 (Figure 5a). Moreover, it was recently shown that 
miR206 inhibits cell growth of ER+ cells66. To assess the differential role of miR221&222 
and miR206 in ER+ cells proliferation, MCF-7 were transfected either with miR206, 
miR221, miR222 and scrambled control and incubated in normal growth condition for up to 
96hrs. MTT-based proliferation assay revealed that miR221 and miR222 increase cells 
proliferation although, as previously reported, miR206 has an inhibitory effect (Figure 5b). 
According to the miR221&222 and miR206 differential effect on p27 protein levels, FACS 
analyses showed that only miR221 and miR222 induce a significant increase in the transition 
from G1 to S phase when compared to the scrambled control (Figure 5c); indeed, a 
significant block in G1 phase was found for miR206 transfected cells and may be responsible  
for the decreased proliferation (Figure 5c). Finally, miR-transfected-MCF7 were subjected to 
gene expression profiles. First, SVD analyses showed that miR-transfected cells werdifferent 
from scrambled-transfected cells (data not shown); notably, miR221- and miR222-
overexpressing MCF7 were clustering together and were separated from miR-206. Statistical 
analyses identified 1966, 1091, 1079 upregulated and 2390, 1014, 936 downregulated genes 
in miR-206, miR221, and miR222 overexpressing cells, respectively. According to these 
gene lists, SVD analyses were further confirmed by two-tailed Fisher's exact test; we showed 
that almost 75% of the genes regulated by miR221 and miR222 were overlapping while only 
the 30% was in common with miR206.  
 Finally, by using Pathway Express on all gene data set, we evaluated also that miR221&222 
modulated-processes are overlapping and different from those of miR206 (Figure 5e). These 
co-regulated-processes are represented by apoptosis, MAPK and TGF-beta signaling 
pathway, focal adhesion and colorectal cancer (Figure 5e). By using only the genes up-
regulated or down-modulated by miR221&222 compared to miR206, we found that main 
activated processes are cell cycle and apoptosis, respectively (data not shown).  
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Figure 5. miR221&222 induce a change in gene expression. a, MCF7 were transfected with scrambled control, miR206, miR-221 
and miR-222 (100nM). ERα and p27 levels were analyzed by western blot analysis. b, Cell growth was measured by an MTT-based 
cell proliferation assay. c, miR-transfected MCF7 were also subjected to FACS analysis and the relative G1,S and G2/M compartments 
calculated. Data are representative of three independent experiments. d, Venn diagram of biological processes modulated by 
overexpression of miR-206, miR221 and miR222 in MCF7 cells. e, List of biological processes modulated by the overexpression of 
miR-206, miR221 and miR222. In red are reported all processes commonly shared by all three miRs, in green by miR206 and miR222, 
in orange by miR221 and miR222.  
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ERα  Negatively Regulates miR221&222 Expression  
Loss of miR221&222 expression in ERα-positive cells also raised the possibility that ERα 
negatively regulates transcription of these miRNAs. To test this hypothesis, first we 
overexpressed ERα in hormone-starved ERα-negative MDA-MB-436 cells (Figure 6a). 
After E2 stimulation, a strong reduction of miR221&222 expression was detected, indicating 
that ERα inhibits miR221&222 expression (Figure 6b). To corroborate this finding, another 
ERα-negative cell line, MDA-MB-231, previously reported to carry the promoter 
hypermethylation of ERα gene67, was treated for 10 days with 5-aza-2’-deoxycytidine 
(5’AZA). This treatment resulted in induction of ERα expression (Figure 6c) that was 
accompanied by reduced expression of miR221&222 (Figure 6d). Next, we investigated 
whether endogenous ERα is involved in miR221&222 down-regulation observed in ERα-
positive cells. siRNA knockdown of ERα was carried out in MCF7 cells (Figure 6e). Highly 
efficient suppression of ERα was accompanied by p27 downregulation and induction of 
miR221&222 expression (Figure 6f). To further confirm the inhibitory effect of ERα on 
miR221&222 expression, T47D cells were treated with the anti-estrogen Fulvestrant, which 
promotes ERα protein degradation through cellular proteosome activation68. Fulvestrant-
treated T47D showed a strong reduction of ERα protein (Figure 6g) and a time-dependent 
induction of miR221&222 expression (Figure 6h). In summary, the enforced expression of 
ERα in ERα-negative cells and the elimination of ERα from ERα-positive cells caused 
inhibition and induction of miR221&222 expression, respectively, demonstrating a novel 
function of ERα as a negative regulator for the expression of these miRNAs.  
Genomic Structure and Transcriptional Regulation of miR221&222 
miR221 and miR222 genes, located on human chromosome X, are tandemly aligned with 
720 nt spacer sequence (Figure 7a). Since the genomic region lacks any protein-coding gene, 
both miRNAs appear to represent a single transcriptional unit. MDA-MB-231 cells, which 
express high levels of miR221&222, were transfected with siRNA against Drosha to produce 
global accumulation of pri-miRNAs69. Western blot analysis demonstrated highly efficient 
Drosha knockdown by siRNA (Figure 7b).  Northern blot analysis of Drosha-knockdown 
cells, probed with genomic DNA fragment spanning pre-miR221, enabled detection of ~2.1  
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kb transcript that is hardly detectable in control cells (Figure 7c, left panel). Detection of the 
~2.1 kb transcript, by reprobing the blot with DNA fragment spanning pre-miR222 (Figure 
7c, right panel), indicated that miR221&222 are transcribed into a single species of pri-
miRNA. To specifically define the 5’ and 3’ termini of the transcriptional unit of pri-
miR221&222, we carried out 5’ and 3’ RACE analyses and found 5’ extension of ~230nt 
from the 3’ end of pre-miR222 and 3’ extension of ~1000nt from the 5’ end of pre-miR221, 
respectively (data not shown). Based on these findings, we assumed that pri-miR221&222 of  
~2.1kb starts around 120nt upstream from the 5’ terminus of miR222 hairpin structure 
(Figure 7a).  
Analysis of miR221/222 gene by using “Promoter.2” and polyA signals database predicted 
two canonical TATA boxes located ~550nt and ~190nt upstream from the 5` end of pre-
miR222 and reiterated polyadenylation sites close to the 3’ end of the primary transcript 
(blue arrow heads and green arrows, respectively in Figure 7a). To determine whether the 
upstream genomic region from the transcription start site functions as a regulator element for 
miR221&222 transcription, we constructed reporter plasmids by inserting the fragments 
spanning -1600 ~ -3000 and +3 ~ -1600 (+1 position corresponds to the 5’ terminus of pre-
miR222) into the promoter-less vector pGL3basic (Figure 7d). Subsequent luciferase assay 
showed that only -1600 pGL3b gave rise to ~9-fold induction of luciferase activity as 
compared to the empty vector (Figure 7d). Next, 5’ end deletion mutants of -1600 pGL3b 
enabled us to map the minimal promoter of miR221&222 gene at -150bp ~ -50bp, where the 
proximal TATA box is excluded (Figure 4d). In summary, both miR221&222 are 
transcribed into a single species of 2.1kb RNA and the transcription is regulated by the 
upstream sequence located at -150bp/-50bp from the 5’ end of miR222 hairpin structure. 
Co-occupancy of ERα and Co-repressor Proteins, NCoR and SMRT, at 
miR221&222 Genomic Region. 
ERα is a nuclear receptor whose activity is regulated by E2. This ligand-dependent activation 
confers two important functions: 1) localization of ERα at the target genes by binding 
specific DNA sequences (Estrogen Responsive Element, ERE) and then 2) recruitment of 
additional transcriptional regulator, termed cofactors, that have either activator or repressor 
function on target genes70. To determine the effect of E2-bound activated ERα on 
miR221/222 gene transcription, hormone-starved MCF7 cells were treated with10nM E2.  
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First, the time-dependent induction of pS2 transcript, a known target of ERα, was evaluated 
after E2 treatment (Figure 8a). In sharp contrast, miR221&222 expression was markedly 
inhibited 24h after the treatment, suggesting that E2-bound ERα functions as a 
transcriptional repressor of miR221/222 gene  (Figure 8b). Another ERα-positive cell line, 
T47D, showed the same ligand-dependent repression of miR221&222 (data not shown). In 
order to investigate whether ERα was bound directly to miR221/222 gene and how it was 
responsible for miR221&222 repression, chromatin immunoprecipitation (ChIP) experiments 
were carried out. First, we searched for ERE as well as AP1 and SP1 binding sites by using 
TESS database (http://www.cbil.upenn.edu/cgi-bin/tess/tess) and found 5 potential EREs 
within the genomic region of 5kb, spanning miR221&222 (Figure 8c). Taking into account 
the predicted ERα binding sites, a total of 3 chromatin regions were analyzed (Figure 8c). 
ChIP assay of ERα-positive MCF7 cells showed remarkable ERα binding at ChIP analyzed 
region 2, which span the promoter of miR221&222 (Figure 8d). No ERα binding was 
observed in ERα-negative MDA-MB-231. Next, we performed ChIP assay against NcoR and 
SMRT and found co-occupancy of these corepressors with ERα in the region 2 (Figure 8d). 
Since no apparent bindings of NcoR and SMRT were detected in the region 1 and 3 of MCF7 
and in all ChIP-analyzed regions of MDA-MB-231, we suggested that ERα is responsible for 
the co-occupancy of the corepressors.  
We next examined the occupancy of E2-activated ERα and the corepressors in MCF7 cells. 
In hormone-starved MCF7 neither ERα nor co-repressors were recruited to miR221/222 gene 
(Figure 8e). Following E2 stimulation, according to the previously reported miR221&222 
repression, all three protein were located to the promoter of miR221&222 (Figure 8e, upper 
panel). Quantitave PCR analyses of the same chromatin showed a strong enrichment of all 
three proteins, ERα, NCoR and SMRT (Figure 8e, lower panel). Finally, applying siRNA-
mediated ERα knockdown to MCF7 cells, we showed that elimination of ERα resulted in 
loss of occupancy of the co-repressors from miR221/222 gene (Figure 8f, upper panel); also 
in this case, qPCR was used to confirm the loss of the three proteins (Figure 8f, lower 
panel). These results leaded us to conclude that ERα, engaged to miR221/222 gene, recruits 
NcoR and SMRT to suppress miR221/222 gene expression.  
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FIGURE8. ERα Binds to miR221/222 Gene and Recruits Corepressor Proteins NCoR and SMRT. a, schematic diagram 
shows miR221&222 transcription unit defined with transcription start site and polyA signal, canonical ERα binding sites 
(yellow triangles), and binding sites for AP1 (black triangle) and SP1 (violet triangle). ChIP-analyzed regions are indicated 
with 3 pairs of the black arrowheads. b, c, MCF7 cells were hormone-starved for 5 days and were then stimulated by adding 
estradiol (E2) at a concentration of 10nM. Total RNAs from E2-treated cells were subjected to qRT-PCR for detection of pS2 
transcipt (b) and mature miR221&222 (c). d, Cross-linked chromatins were prepared from MDA-MB-231 (ERα-negative) 
and from MCF7 (ERα-positive) cells and were subjected to ChIP assay. Input indicates 5% portion of ChIP input. e, MCF7 
cells were hormone-starved for 5 days and were then stimulated by adding estradiol (E2) at a concentration of 10nM. 24hr 
after stimulation, cells were cross-linked and were subjected to ChIP assay.  f, MCF7 cells were tranfected with siRNA 
against ERα or control siRNA. 72hr after transfection, siRNA-treated cells were cross-linked and were subjected to ChIP 
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DISCUSSION 
In this study, we have shown that the bicistronic miR221&222 are consistently up-regulated 
in ERα-negative cell lines and primary breast tumors. Subsequent identification of ERα as a 
target of miR221&222 highlighted the importance of these miRNAs in the regulation of ERα 
expression in breast tumor. A recent study showed that miR206, originally identified as an 
upregulated miRNA in ERα-negative breast tumors59, targets ERα transcript as well60. 
Therefore, it seems like that multiple miRNAs regulate ERα expression in a combinatorial 
manner. Several studies62-65 describe that miR221&222 target the tumor suppressor protein 
p27kip1. In fact, we found that p27kip1 protein was repressed only in cells overexpressing miR-
221&222 but not in cells overexpressing miR-206. Inhibition of miR221&222 induces 
apoptosis in ERα-negative cells64; moreover, as recently published, over-expression of 
miR206 in estrogen-dependent MCF7 cells inhibits cell growth in a dose- and time-
dependent manner66. Furthermore, microarray analyses highlighted that overexpression of 
miR221&222 compared to miR206 in ERα-positive cells induces a specific activation of cell 
cycle and inhibition of apoptosis. Between the other biological pathway modulated by 
miR221&222, we found also the TGF-beta signaling pathway. Although, TGF-beta promotes 
cell growth inhibition, apoptosis and differentiation, and therefore, is considered a potent 
tumor-suppressor71, recent studies indicated that TGF-beta plays a dual role in breast 
tumorigenesis; in fact, during advanced stages of breast cancer, TGF-beta factually 
stimulates cancer cell invasion and metastasis72. Notebly, also the focal adhesion pathway 
were strongly modulated by miR221 and miR222 overexpression; modulation of this process 
may confer to the cancer cells the ability to survive the apoptotic pressure of anchorage 
indipendent-conditions73.  According with these data, the induction of miR-221&222 could 
confer a more effective proliferation advantage to the ERα-positive cells compared to 
miR206: notably, the suppression of ERα associated with low levels of p27 kip1 and 
modulation of other players not still defined will allow into the ERα-positive cells an 
estrogen-independent proliferation, an increase in cell cycle progression, tumor invasion and 
metastasis.  
 The loss of miR221&222 expression in ERα-positive cells and tumors, evidenced by 
Northern blot and qRT-PCR analyses, led us to investigate the involvement of ERα in 
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miR221&222 expression. Both gain and loss of function studies revealed that ERα inhibits 
miR221&222 expression. For example, we demonstrated that over-expression of ERα in 
ERα-negative cells reduces miR221&222 levels, explaining also the  p27 induced-apoptosis 
after ERα restoration in ERα-negative cells74.  
 Since accumulation of either primary transcript or precursor species encoding these 
miRNAs was not evident in Northern blot analysis of ERα-positive cells (data not shown), 
the suppression of miR221&222 mediated by ERα does not appear related to a block in 
microRNA processing; rather, our results revealed that ERα functions as a transcriptional 
repressor for miR221/222 gene expression. While much is known about the mechanisms by 
which estrogen-bound ERα stimulates gene expression, the molecular mechanism(s) 
underlying gene repression caused by the hormone-ERα complex is largely unknown. 
Accumulating data concerning ERα-mediated transcriptional regulation suggest that, in 
general, estrogen-bound ERα recruits activator proteins, while in condition of hormone 
depletion, ERα recruits corepressor proteins thereby allowing the receptor to function as a 
transcriptional activator or repressor of its target genes75. We showed that in ERα-positive 
cells, either under regular culture condition or after E2-stimulation, ERα caused 
downregulation of miR221&222. Interestingly, we found that ERα is strongly bound to the 
miR221/222 gene promoter and, in turn, it is responsible for the recruitment of co-repressor 
proteins NCoR and SMRT. Regarding other examples of corepressor recruitment by E2 
activated ERα, transcriptional repression of cyclin G2 gene76 and of vascular endothelial 
growth factor receptor 2 genes77 have been recently reported. It is intriguing that both studies 
showed an involvement of Sp proteins for the recruitment of corepressor proteins at 
respective promoters. GC-rich stretch, a favorable site for SP1 protein binding, was also 
found in the region of miR221&222 promoter. Further study is needed to determine whether 
SP protein is involved as well in transcriptional repression of miR221/222 gene mediated by 
ERα. 
In summary, we showed that miR221&222 target ERα mRNA and that ERα functions as a 
transcriptional repressor of miR221/222 gene. Hence (Figure 9), the three components build 
a molecular circuitry whose deterioration may trigger an alteration of ERα expression status 
in breast cancer cells. Such molecular network would provide a foundation to understand  
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Figure 9. ERα  constitutes a regulatory circuitry with miR221&222. Our results suggest a model in 
which estrogen bound-ERα represses miR221&222 expression. Mitogenic stimuli, as over-expression 
and continuous activation of ErbB2, induce through a molecular mechanism still unclear loss of ERα 
which in turn mediates miR221&222 gene activation. The endpoint of gain of miR221&222 expression 
is suppression of ERα as well as of p27(Kip), which may be critical for establishing ER-negative status 
and producing de-regulated cell proliferation.   
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how ERα-positive breast tumors become ERα-negative, a frequent observation with 
profound impact on clinical outcome in recurrent breast cancer. 
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APPENDIX 
 
Table 1. Examples of functions of microRNAs in animals. 
miRNA Species Function 
lin-4 C.elegans Regulation of life span (proportionally with expression) 
miR-273 C. elegans Controls laterality of the chemosensory system 
miR-1 Drosophila Post-mitotic growth of larval muscle 
miR-2, miR-6, miR-11, 
miR-13, miR-308 
Drosophila Suppress embryonic apoptosis by posttranscriptional repression 
of proapoptotic factors  
miR-2, miR-13 Drosophila Normal development of head and posterior abdominal segments 
miR-7 Drosophila Promotes photoreceptor differentiation 
miR-14 Drosophila Suppression of cell death; normal fat metabolism 
miR-278 Drosophila Control of energy homeostasis by influencing insulin production 
and adipose-tissue glycogen stores. 
Bantam Drosophila Controls cell proliferation and prevents apoptosis 
miR-1-1 Mouse Control of balance between differentiation and proliferation 
during cardiogenesis 
miR-122 Mouse Regulator of cholesterol and fatty-acid metabolism 
miR-142s Mouse B lymphocyte differentiation; 
myeloid differentiation 
miR-181 Mouse B lymphocyte differentiation 
Myoblast differentiation by targeting Hox-11 
miR-196 Mouse Limb development, acting upstream of Hoxb8 and Sonic 
hedgehog 
miR-200a, miR-141, 
miR-429, miR-199a 
Mouse Skin morphogenesis 
miR-223 Mouse, 
Human 
Myeloid differentiation 
Regulation of granulopoiesis 
miR-15a, miR-16-1 Human Regulation of B lymphocytes survival 
miR-375 Human Regulation of insulin secretion 
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Table 2. Examples of microRNAs involvement in human diseases. 
 
  Cancer types miRNA involvement 
Human leukemias and 
carcinomas 
~ 50% of miRNAs located in minimal LOH/Amplified regions; 
microRNAs expression profiles classify human cancers 
B cell CLL Deletions and down regulation of miR-15a and miR-16-1 
MiRNA profiles associates with survival and clinical parameters; 
Germline and somatic mutations in miRNA genes; 
miR-15 and miR-16 target BCL2 
Pediatric Burkitt’s  
Lymphoma 
High expression of precursor for miR-155/BIC 
B cell lymphomas Accumulation of miR-155 and BIC RNA; 
BIC and miR-155 are highly expressed 
Human lymphomas Overexpression of pri-miRNA-17-92 cistron 
Lung cancers miRNA profiles associates with survival and clinical parameters 
Breast cancers miRNA profiles associates with survival and clinical parameters 
Thyroid cancers Germline polymorphisms with possible functional consequences in c-KIT 
oncogene interactions sites with miRNAs.  
Tourette’s syndrome Polymorphisms with possible functional consequence in SLITRK1 interaction 
site with a miRNAs. 
Fragile X syndrome Loss of expression of the FMPR protein, that interact with members of the 
miRNA pathway 
Spinal muscular atrophy 
(SMA) 
Reduced expression of SMN protein, involved in RNP complexes containing 
miRNAs 
Di George syndrome Loss of expression of DGCR8 protein, a Drosha interactor in human cells 
 
* NR – not reported; LOH – loss of heterozygosity; BIC gene - noncoding RNA transcript 
located at chromosome 21q21.3. pre-miRNA155 is likely processed from a transient spliced 
or unspliced nuclear BIC transcript; FMPR – fragile X mental retardation protein; SMN – 
Survival of Motor Neurons protein; RNP – ribo-nucleo-proteins; DGCR8 – Digeorge 
syndrome critical region gene 8. 
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TABLE 3: miRNAs differentially expressed in ER-positive versus ER-negative breast 
cancer cells. 
miRNAs differentially expressed in ER-positive versus ER-negative breast cancer cells 
microRNA genes UP-REGULATED in ER positive-breast cancer cells 
microRNA genes p-value Fold Change 
hsa-mir-203 1.07E-05 77.779 
hsa-mir-375 4.56E-05 45.61 
hsa-mir-200c 0.0003528 23.207 
hsa-mir-10b 1.24E-05 22.78 
hsa-mir-425 8.00E-06 15.739 
hsa-mir-370 7.00E-07 13.553 
hsa-mir-148b < 1e-07 13.026 
hsa-mir-200a 0.0004639 12.657 
hsa-mir-200b 0.002323 9.733 
hsa-mir-15b 3.61E-05 8.863 
hsa-mir-423 3.22E-05 8.114 
hsa-mir-365-2 < 1e-07 7.94 
hsa-mir-148a 3.00E-07 7.926 
hsa-mir-345 4.70E-06 7.603 
hsa-mir-342 4.60E-06 7.03 
hsa-mir-34b < 1e-07 6.929 
hsa-mir-15a 0.0001047 5.548 
hsa-mir-141 0.0046452 5.487 
hsa-mir-183 0.0010602 5.169 
hsa-mir-196a-1 0.0002206 5.112 
hsa-mir-26a-2 2.94E-05 5.039 
hsa-mir-191 2.00E-07 4.993 
hsa-mir-190 < 1e-07 4.848 
hsa-mir-1-1 0.0022543 4.811 
hsa-mir-10a 0.0187181 4.775 
hsa-mir-26a-1 7.92E-05 4.478 
hsa-mir-181b-1 0.0004517 4.117 
microRNA genes DOWN-REGULATED in ER positive-breast cancer cells 
hsa-mir-155 0.0012452 0.235 
hsa-mir-494 0.004397 0.185 
hsa-mir-218-1 7.74E-05 0.182 
hsa-mir-31 1.00E-07 0.111 
hsa-mir-146 0.0199231 0.105 
hsa-mir-138-2 7.85E-05 0.064 
hsa-mir-222 < 1e-07 0.011 
hsa-mir-221 < 1e-07 0.002 
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Table 4: Characteristics of breast tumors and patients 
 
 
 
ER+ 
 
ER- 
 
Total number of patients 
 
44 
 
22 
 
Tumor size (cm) 
 
 
 
 
 
≤2 
 
16 
 
8 
 
>2 
 
28 
 
14 
 
Menopause 
 
 
 
 
 
Yes 
 
33 
 
6 
 
No 
 
11 
 
16 
 
No. of posistive lymph nodes 
 
 
 
 
 
0 
 
10 
 
7 
 
1-3 
 
20 
 
5 
 
>3 
 
14 
 
10 
 
p53 status 
 
 
 
 
 
negative 
 
37 
 
8 
 
positive 7 14 
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conserved “seed region” 
miR-221 
miR-222 
cER 3`UTRwt 5'   ....AUGACAGACAAUCUUAUGUAGCA..
. 
3'    CUUUGGGUC-GUCUGU---UACAUCGA 
3'    CUCUGGGUCAUCGGUC--UACAUCGA 
miR-221 
miR-222 
cER 3`UTRmut 5'   ....AUGAGGCACAAUCUUGGGGGGGA..
. 
3'    CUUUGGGUC-GUCUGU---UACAUCGA 
3'    CUCUGGGUCAUCGGUC--UACAUCGA 
c) d) 
miR221&222 seed 
CCUAUUGUUGGAUACUGAAUGACAGACAAUCUUAUGUAGC------AAAGAUUAUGCCUGAAAAGGA---------AAAUUAUUCA 
CCUAUUGCUGGGUGUUGAAUGACAGACAAUCUUAUGUAGC------AGAGAUUAUGCCUGGGAAGGA---------AAAUUAUUCA 
CCUAUUGUUGGAUGUUGAAUGACAGACAAUCUUAUGUAGC------AGAGAUUAUGCCUGAGAAGGA---------AAAUUAUUCA 
CCUAUUGUUGGAUAUCGAACGAUAGACAAUCUUAUGUAGC------AGAGAUUAUGCCUGCAAAGGA---------AAAUUAUUCA 
CCUGGUGCUGGAUAUUAAACAA-AGAUA----UAUAUAGCAUGUUAAAAAAAAAAAAAAGAAAAAGAAUUUAAAGUAAACUAUUCA 
H
s M
m R
n C
f G
g 
a) conserved “seed region” 
b) 
miR221&222 seed 
non-conserved “seed region” 
AAAGUGGUACACCUUAAAGCUU--------UUAUAUGACUGUAGCAGAGUAUCUGGUGAUUGUCAAUUCAUUCCCCCUAUAGGAAUA H
s M
m R
n C
f G
g 
AAAGGGA----------------------------------------AAUCUUGAG-----------------CCCCUAUAGGAAUA 
AAAGGGA----------------------------------------AAUCUUGAG-----------------CCCCUAUAGGAAUA 
AAAGUAA--UACCUUAAAGCUUUUGCUCUGUUGCAUGGCUGGAGCUGAAUAUGCAGUGAUUGUCUCUUCAUUUGCCCUAUAGGAAUA 
--------------------------------------------------------------------------------------- 
Figure S1. miR221&222 Binding Sites in the ERa 3`UTR a,b schematic representation of the conserved 
(a) and non-conserved (b) miR221&222 binding sites in the ERa 3`UTR; because of the perfect  homology 
between the seed regions of miR221&222, both miRNAs are able to target the same sequence in the 
3`UTR. Lower part of each panel shows mutations introduced into the binding site and the resultant 
disruption of homology against miR221&222 (indicated by red lines). 
 
miR-221 
miR-222 
ncER 3`UTRmut 5'  .... AAGCUUUUAUAUCGG----GCGGCGAG... 
3'    CUUUGGGUC-GUCUGUUACAUCGA 
 
3'    CUCUGGGUCAUCGGUC--U--ACAUCGA 
 
non-conserved “seed region” 
miR-221 
miR-222 
ncER 3`UTRwt 5'   ....  AAGCUUUUAUAUGAC----UGUAGCAG... 
3'    CUUUGGGUC-GUCUGUUACAUCGA 
 
3'    CUCUGGGUCAUCGGUC--U--ACAUCGA 
CUCUGGGUCAUCGGUCUACAUCGA 
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Primers 
a) Luciferase assay cloning:  
conserved miR221&222 seed region: 
cERα3UTR wt Forw: 5` tctagaatgtgcacttaaatttggggaca 3` 
cERα 3UTR wt Rev: 5`tctagacccagattcctgaatccacttcc 3`  
 
non-conserved miR221&222 seed region: 
ncERα3UTR wt Forw: 5`tctagaggctctaagaataagccacagc 3` 
ncERα3UTR wt Rev: 5` tctagactgccttccctgtgtgcccctt 3` 
 
miR221&222 Promoter: 
-3000/-1600 pGL3b Forw: 5`gctagcacttccacatatagtccctagggtc 3` 
-3000/-1600 pGL3b Rev: 5` ctcgagaccagtgtggttagctcttggtggg 3`  
-1600 pGL3b Forw: 5`gctagccccaccaagagctaaccacactggt 3` 
-1000pGL3b Forw: 5` gctagccctagccaccttatcgaaaatagcattcc 3` 
-600 pGL3b Forw: 5` gctagcctgacatgctagtgagcacctgc 3` 
-200 pGL3b Forw: 5`gctagcgtttgctgctggatctccagcacc 3` 
-150 pGL3b Forw: 5`gctagcccagaggttgtttaaaattacgta 3` 
-50 pGL3b Forw:  5` 
ctagctagctagcttttttcttccacagagccctccccagaaggcaaaggatcacccagctccgctcgagcgg 3`  
-50 pGL3b Rev: 5` 
ccgctcgagcggagctgggtgatcctttgccttctggggagggctctgtggaagaaaaaagctagctagctag 3` 
miR222 pGL3b Rev: 5` ctcgagagctgggtgatcctttgccttctg 3` 
 
b) miR221 probes for Agarose Northern blot: 
miR221 UP forward: 5`cttgaatgcagtaggcagttgtgt 3` 
miR221 Down reverse: 5` ctccactggtttatacctcctgga  3` 
 
miR222 UP forward: 5`gtcactcagtcagtatctgttgga 3` 
miR222 Down reverse: 5` gtgtgtaattcaaggtaaagttttc 3` 
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c) ERα  expressing vectors: 
forward primers: 5` ggtaccatgaccatgaccctccacaccaaagc 3` 
reverse primers: 5` gatatcccgtgtgggagccagggagctctcag 3` 
d) Chromatin Immunoprecipitation primers: 
1F: 5`ggattctaagacgtgtacttggag 3` 
1R: 5` cttgcactcacggaagtttaagtc 3` 
2F: 5` gtcactcagtcagtatctgttgga  3` 
 2R: 5` gtgtgtaattcaaggtaaagttttc 3`  
3F: 5` ctacctacctacctatctacccct 3 ` 
3R: 5` caacagtcagaaatgctgggactt 3`   
 4F: 5`cttgaatgcagtaggcagttgtgt 3` 
4R: 5`ctccactggtttatacctcctgga 3` 
 
 
 
 
 
 
 
 
